Supplementary Figure S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with &lt;i&gt;MDM2&lt;/i&gt; Amplification: An Open-Label Phase Ib/II Study